1. Home
  2. AIRT vs NBP Comparison

AIRT vs NBP Comparison

Compare AIRT & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air T Inc.

AIRT

Air T Inc.

N/A

Current Price

$21.54

Market Cap

87.8M

ML Signal

N/A

NBP

NovaBridge Biosciences American Depositary Shares

SELL

Current Price

$0.83

Market Cap

96.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AIRT
NBP
Founded
1980
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.8M
96.0M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
AIRT
NBP
Price
$21.54
$0.83
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $8.67
AVG Volume (30 Days)
24.5K
★ 526.3K
Earning Date
11-13-2026
08-20-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1393.72
N/A
EPS
N/A
★ N/A
Revenue
★ $286,834,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 15.98
N/A
52 Week Low
$18.40
$0.75
52 Week High
$35.00
$5.19

Technical Indicators

Market Signals
Indicator
AIRT
NBP
Relative Strength Index (RSI) 27.37 30.80
Support Level $20.22 N/A
Resistance Level $23.74 $1.45
Average True Range (ATR) 1.78 0.07
MACD -0.60 0.01
Stochastic Oscillator 18.01 31.05

Price Performance

Historical Comparison
AIRT
NBP

About AIRT Air T Inc.

Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include overnight air cargo, ground support equipment, commercial aircraft, engines and parts, digital solutions, and regional airline. The company generates maximum revenue from the overnight air cargo segment.

About NBP NovaBridge Biosciences American Depositary Shares

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.

Share on Social Networks: